In comparison to biologics for psoriasis, such as TNF-α inhibitors (e.g., infliximab, adalimumab), IL-12/23 inhibitors (e.g., ustekinumab), IL-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., guselkumab, risankizumab) that target specific cytokines involved in inflammatory pathways, deucravacitinib offers a unique mechanism of action. This evidence concerns the gene IL17A and psoriasis.